Operates two business segments: Speciality Chemicals & Pharma Intermediates and Logistics Services. In FY26 consolidated revenue was Rs 52.71 crore with a 15.96% EBITDA margin and net profit of Rs 5.32 crore. In the quarter ended 31 March 2026 the specialty chemicals segment booked Rs 16.88 crore of revenue and Rs 1.25 crore of EBIT, while Logistics Services contributed Rs 1.46 crore of revenue and Rs 0.29 crore of EBIT. The group consolidates subsidiaries Eiko Scientific Solutions LLP and Eikovivify Logistics and associate Reflux Pharmaceuticals, and in January 2026 took a 31.68% stake in SSM Formulations Private Limited, a WHO-GMP pharmaceutical formulations manufacturer based in Hinganghat Wardha. Raw materials are by far the largest cost at 78.3% of revenue, with capex at 0.0% of revenue in FY26. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Speciality Chemicals & Pharma Intermediates, Logistics Services. Small specialty chemicals and logistics group, consolidating via subsidiaries and an associate
| ₹ crore · consolidated | FY20 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 10 | 38 | 53 |
| EBITDA (ex other income) | (5) | 3 | 7 |
| margin % | (44.0) | 8.2 | 14.1 |
| Owners' profit | (2) | 2 | 4 |
| EPS, as reported (₹) | (4.99) | 1.62 | 3.26 |
| ROE % · ROCE % | (325.5) · (172.4) | 4.1 · 5.1 | 7.6 · 10.0 |
| Debt / equity (x) | 1.45 | 0.05 | 0.07 |
| Cash from operations | — | 3 | 2 |
| Capex | — | (10) | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11 | 8 | 7 | 11 | 11 | 12 | 12 | 18 |
| Profit before tax | 0 | 0 | 1 | 2 | 1 | 2 | 2 | 2 |
| Net profit | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| EPS (₹) | 0.29 | 0.22 | 0.32 | 0.80 | 0.66 | 0.78 | 0.88 | 0.93 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Speciality Chemicals & Pharma Intermediates | 27 | 51.5 |
| Logistics Services | 4 | 8.3 |
| Specialty Chemicals & Pharma Intermediaries | 10 | 19.9 |
| Specialty & Fine Chemicals | 8 | 15.9 |
| Logistics Business | 2 | 4.4 |
| Total, before eliminations | 53 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 27 Aug 2026 · 49th AGM notice and annual report dispatch - 22 Sep 2026 | compliance | minimal | — | — |
| 25 Aug 2026 · Eiko Lifesciences sets 22 September 2026 AGM through video conference | compliance | minimal | — | — |
| 24 Aug 2026 · Eiko LifeSciences files 49th Annual Report for FY26, AGM on 22 Sept 2026 | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Eiko Lifesciences 49th AGM on Sept 22 via video conferencing for FY25-26 | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Independent Director Hasti Doshi resigns from Eiko Lifesciences | management changes | medium | — | — |
| 24 Aug 2026 · Appointment of new Independent Director Mr. Suraj Mahadev Gaikwad | management changes | medium | — | — |
| 24 Aug 2026 · Eiko Lifesciences: Independent Director resigns, new director appointed, AGM set | management changes | medium | — | — |
| 18 Aug 2026 · Old IDBI Bank corporate guarantee claim received; company disputes | regulatory legal | high | — | — |
| 18 Aug 2026 · 305000 Warrants Converted to Equity Shares at Rs 55 Each | fund raising | medium | — | — |
| 13 Aug 2026 · Eiko Lifesciences Q1 FY27 results published in newspapers | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| PIDILITE INDUSTRIES LTD | 1,59,479 | 60.2 | 14.43 | 42.3 | 22.4 | 28.0 | 14.9 | 28.6 |
| SRF LTD | 73,583 | 34.0 | 5.24 | 22.7 | 13.1 | 13.1 | 13.4 | 25.2 |
| GUJARAT FLUOROCHEM LTD | 52,514 | 85.7 | 6.64 | 41.5 | 7.3 | 8.7 | 13.5 | 27.7 |
| NAVIN FLUORINE INT. LTD | 43,836 | 55.4 | 11.03 | 39.5 | 16.7 | 16.4 | 23.0 | 37.5 |
| AETHER INDUSTRIES LIMITED | 22,229 | 94.3 | 9.05 | 60.4 | 8.9 | 11.4 | — | 33.8 |
| DEEPAK NITRITE LTD | 21,769 | 27.8 | 3.71 | 22.4 | 9.4 | 10.2 | 12.6 | 21.5 |
| ATUL LTD | 18,401 | 23.1 | 2.92 | 14.9 | 10.9 | 13.3 | 10.9 | 23.1 |
| AARTI INDUSTRIES LTD | 17,846 | 33.6 | 3.00 | 18.8 | 7.0 | 4.4 | 13.0 | 16.2 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 14.1 | 23.4 | 23 of 103 | 78% |
| P/B | 0.9 | 2.9 | 8 of 99 | 93% |
| ROCE | 9.6 | 10.3 | 57 of 108 | 48% |
| ROE | 7.6 | 8.1 | 56 of 101 | 45% |
| Debt / Equity | 0.1 | 0.2 | 42 of 101 | 59% |
| EBITDA margin | 13.2 | 15.5 | 60 of 99 | 40% |
| Revenue growth | 62.7 | 24.4 | 12 of 94 | 88% |
| Profit growth | 20.4 | 55.1 | 60 of 92 | 35% |
| Market cap | 66 | 732 | 86 of 107 | 20% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
